Longevity Health, True Health to combine in all-stock transaction
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 14 2025
0mins
Should l Buy ?
Merger Announcement: Longevity Health has entered into a definitive merger agreement with True Health in an all-stock transaction, with plans to trade under the symbol (XAGE) on Nasdaq after closing, which is expected in Q4 2025.
Financial Projections and Leadership Changes: True Health's THPlasma business is projected to achieve significant revenue growth and profitability, while leadership will transition with Rajiv Shukla as executive chairman and George Chi as co-chairman and CEO post-merger.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
